Kiromic BioPharma, Inc. Common Stock
KRBP
KRBP was delisted on the 13th of September, 2023.
16 hedge funds and large institutions have $90.3K invested in Kiromic BioPharma, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 6 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
6% less funds holding
Funds holding: 17 → 16 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
55% less capital invested
Capital invested by funds: $200K → $90.3K (-$110K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.81K |
| 2 |
SG
StoneX Group
New York
|
+$5.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.16K |
| 4 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
+$4.06K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$1.54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$33K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$15K |
| 3 |
Millennium Management
New York
|
-$13K |
| 4 |
VF
Virtu Financial
New York
|
-$11K |
| 5 |
SC
Shay Capital
New York
|
-$7K |
KRBP Hedge Fund Activity: Q3 2022 in Review
16 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q3 2022, worth a combined $90.3K — down 55% from $200K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of KRBP and 5 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, adding an estimated $7.81K. The largest seller was HRT Financial, exiting entirely with an estimated $33K sold.
- 16 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q3 2022, down from 17 in Q2 2022.
- Funds reported $90.3K of Kiromic BioPharma, Inc. Common Stock stock for Q3 2022, down 55% quarter-over-quarter.
- 5 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q3 2022 and 6 closed out, a net change of -1 holder.
- The largest Kiromic BioPharma, Inc. Common Stock buyer in Q3 2022 was Citadel Advisors, an estimated $7.81K added.
- The largest Kiromic BioPharma, Inc. Common Stock seller in Q3 2022 was HRT Financial, an estimated $33K sold.
Based on aggregated 13F filings for Q3 2022.